Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Rat ITGAV&ITGB3 Heterodimer, His Tag&Tag Free, produced by co-expression of ITGAV and ITGB3, has a calculated MW of 112.3 kDa (ITGAV) & 81.6 kDa (ITGB3). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and subunit ITGB3 contains no tag but a basic tail at the C-terminus. The protein migrates as 125-145 kDa (ITGAV) and 70-85 kDa (ITGB3) when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Rat ITGAV&ITGB3 Heterodimer, His Tag&Tag Free on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
The purity of Rat ITGAV&ITGB3 Heterodimer, His Tag&Tag Free (Cat. No. IT3-R52E2) is more than 85% and the molecular weight of this protein is around 210-240 kDa verified by SEC-MALS.
Immobilized Human Vitronectin at 5 μg/mL (100 μL/well) can bind Rat ITGAV&ITGB3 Heterodimer, His Tag&Tag Free (Cat. No. IT3-R52E2) with a linear range of 0.039-1.25 μg/mL (QC tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
(68)Ga-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Keloid | Details | |
Antiangiotide | HM-3; IIM-3 | Phase 1 Clinical | Inner Mongolia Tianqi Pharmaceutical Group Co Ltd, China Pharmaceutical University | Liver Neoplasms; Solid tumours; Stomach Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
MK-0429 | MK-429; MK-0429; L-000845704 | Merck Sharp & Dohme Corp | Details | ||
Pagantangentide | Phase 1 Clinical | Nanjing Anji Biological Technology Co Ltd, Jiangsu Aotexin Biomedical Technology Co Ltd, China Pharmaceutical University | Arthritis, Rheumatoid; Rheumatic Diseases | Details | |
IDL-2965 | IDL-2965 | Phase 2 Clinical | Indalo Therapeutics Inc | Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis | Details |
ProAgio | Phase 1 Clinical | National Cancer Institute | Solid tumours; Pancreatic Neoplasms | Details | |
68Ga-NOTA-3PTATE-RGD | 68Ga-NOTA-3PTATE-RGD; 68Ga-NOTA-3P-TATE-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Neuroendocrine Tumors; Lung Neoplasms | Details |
99mTc-3PRGD2 | 99mTc-3PRGD2 | Phase 3 Clinical | Peking University | Lymphatic Metastasis; Lung Neoplasms | Details |
68Ga-NOTA-BBN-RGD | 68Ga-NOTA-BBN-RGD | Phase 1 Clinical | Peking Union Medical College Hospital | Breast Neoplasms; Prostatic Neoplasms | Details |
Alfatide[18F] | 18F-AlF-NOTA-PRGD2; 18F-alfatide; alfatide II; AlF-NOTA-PRGD2-[18F] | Phase 3 Clinical | Jiangsu Smk Pharmaceutical Co Ltd, Taizhou Kairui Pharmaceutical Technology Co Ltd | Carcinoma, Bronchogenic; Head and Neck Neoplasms; Neoplasms; Soft Tissue Neoplasms; Contrast agents; Breast Neoplasms; Lymphoma | Details |
BGC-0222 | BGC0222; BGC-0222 | Phase 1 Clinical | Gaorui Yaoye (Beijing) Technologies Co Ltd, Brightgene Bio-Medical Technology Co Ltd | Solid tumours | Details |
Ga-68 NODAGA-RGD | [68Ga]Theranost; Theranost 68Ga-RGD | Phase 1 Clinical | Advanced Imaging Projects, Zentralklinik Bad Berka, National Cancer Institute | Neovascularization, Pathologic; Prostatic Neoplasms; Contrast agents; Breast Neoplasms; Brain Neoplasms; Lung Neoplasms | Details |
fb-PMT | NP-100; NP-751 | Phase 1 Clinical | NanoPharmaceuticals LLC | Glioma | Details |
OTT-166 | OTT-166 | Phase 2 Clinical | OcuTerra Therapeutics Inc | Diabetic Retinopathy | Details |
[68Ga]-FF58 | Phase 1 Clinical | Novartis Pharma Ag | Stomach Neoplasms; Esophageal Neoplasms; Glioblastoma; Brain Neoplasms; Carcinoma, Pancreatic Ductal | Details |
This web search service is supported by Google Inc.